

Active Ingredient Summary Table

Alopecia

Active Pharmaceutical Ingredient	Mechanism of Action (MoA)	Type of Alopecia Treated/Treatment Group	Dosing	Studies
Adapalene	Recent studies propose that retinoids have an impact on the enzyme that converts minoxidil to its active form, follicular sulfotransferase, and may increase response to minoxidil via increased expression of this enzyme ⁷⁶ Retinoids also impact generation and differentiation of hair follicles. ⁸²	Alopecia areata in male and female patients, though, the mechanism could apply to androgenetic alopecia as well	Adapalene 0.1% in combination with mometasone 0.1% once daily	One small study compared adapalene 0.1% gel in combination with mometasone furoate 0.1% cream applied once daily vs twice daily mometasone alone for patients with alopecia areata. The study found mean hair growth to be statistically significantly greater with combination treatment at the 4, 8, and 12 week timepoints. ⁸²
Anthralin	The mechanism for anthralin in alopecia areata has not been fully elucidated, it is primarily used topically for psoriasis as it has anti-proliferative effects, it may also have anti-inflammatory effects	Alopecia areata, tested in men and women ^{31,33}	0.5-1% cream applied topically daily	Results concerning anthralin are mixed, one study evaluating 0.5%-1% cream found response in 25% of patients, but another in combination with minoxidil found only 11% acceptable hair regrowth ^{33,34}
Azelaic Acid	Inhibits 5-alpha-reductase, involved in inhibiting conversion of testosterone to DHT ⁵⁰	Alopecia areata, tested in men and women ⁴⁸	20% cream for alopecia areata ⁴⁸ , 1.5% in combo with minoxidil 5%, caffeine 1% also tested ⁴⁹	Study evaluating azelaic acid 20% vs anthralin over 12 weeks. Treatments were found to be equally effective for both treatment groups ⁴⁸ Azelaic acid 1.5% with minoxidil 5%, caffeine 1% demonstrated superior to minoxidil alone in placebo controlled 32 week trial.

Active Ingredient Summary Table

Alopecia

Betamethasone	Immune suppression, as an autoimmune disorder, alopecia areata can be treated by immunosuppressant drugs	Alopecia areata, less effective for alopecia totalis and alopecia universalis, can be for men or women	0.1% betamethasone valerate foam preferred over 0.05% lotion ^{31,32}	Study evaluating betamethasone valerate foam vs betamethasone dipropionate lotion found 61% of those on betamethasone valerate achieved more than 75% hair regrowth compared to only 27% in the lotion group. ³¹
Bexarotene	Vitamin A related compound that binds to retinoid X receptors. Mechanism not entirely clear, but may be similar to tretinoin (i.e. causing contact dermatitis)	Alopecia areata, tested in men and women	1% gel	Study found that 12% of patients had 50% or more partial hair regrowth on the treated side, 14% on both sides, however, many of the patients experienced irritation in response to treatment ³⁸
Bimatoprost	Prostaglandin mediated anagen induction. Latanoprost and bimatoprost are prostaglandin analogues ²⁰	Alopecia areata and androgenetic alopecia	0.03% topical solution	Study evaluating bimatoprost 0.03% topical solution twice daily for three months vs mometasone furoate for alopecia areata found the bimatoprost to be significantly more effective. ⁵⁴ Another study comparing it to 5% minoxidil also found no statistically significant difference between the two groups regarding hair growth. ⁵⁵
Biotin	Biotin, Vitamin B7, is a common oral supplement for hair loss however despite biotin deficiency being a common finding in women experiencing hair loss ⁴² mechanism of action is not totally clear. Could be related to mitochondrial function in hair root cells as a cofactor ⁴³	Most studies evaluate oral biotin between 1-10mg and find benefit in patients with genetic or iatrogenic reasons for hair loss ⁴⁴	Though no studies currently exist that I could find, if biotin is used it is often between 0.1-0.5%	Though studies on the benefit of oral supplementation have demonstrated benefit in specific populations, studies on topical use are not yet available. Evidence for use is mainly anecdotal.

Active Ingredient Summary Table

Alopecia

Caffeine	A possible mechanism is increased cAMP via phosphodiesterase inhibition resulting in increased cell proliferation of follicles (combating DHT induced miniaturization of the follicle) ²³	Androgenetic alopecia tested, though possible use in other non-cicatricial alopecia types. Tested in men	0.2% topical liquid	One open-label non-inferiority trial testing caffeine 0.2% topical liquid as compared to minoxidil 5% solution found caffeine to be as effective as minoxidil at increasing the amount of anagen hairs over a 6-month period. ²³
Cetirizine	Cetirizine has some anti-PGD2 activity, prostaglandin D2 has been implicated as a causative factor in some alopecias ⁴⁶	Studied in androgenetic alopecia	1% topical cream or liquid	Study evaluating cetirizine 1% vs placebo noted significant improvement in total hair density and decrease in vellus hair density. No adverse effects reported ⁴⁶
Clascoterone	Clascoterone is an androgen receptor inhibitor, though trials are still underway, it may help by decreasing the impact of androgens on hair follicle miniaturization on the scalp. ⁵⁹	Studies underway for treatment of androgenetic alopecia	5-7.5% solution applied twice daily	One phase II trial of clascoterone vs placebo found significant improvement with clascoterone compared to vehicle. ⁶⁰
Clobetasol propionate	Clobetasol as a steroid may have immunosuppressive benefits in the management of alopecia areata	Alopecia areata ²⁵ Studied in men and women as well as children	0.05% topical cream or ointment	Study of 28 patients with alopecia areata who applied 2.5g of 0.05% ointment for 6 months to one side of scalp resulted in some regrowth for 28.5% of patients ²⁶
2-Deoxy-D-ribose (note, this does not qualify for compounding)	Stimulation of revascularization to promote hair growth ⁷⁸	Androgenetic alopecia in male and female patients ⁷⁸	0.394% studied in vitro	Currently limited to animal trials
Diclofenac Sodium	May cause regrowth of hair via mitigation of perifollicular micro-inflammation and correcting prostaglandin imbalance. ⁸⁵	Limited case studies in male patients with androgenetic alopecia and alopecia areata	Diclofenac 3% gel once nightly in androgenetic alopecia study, diclofenac 1% applied twice daily in alopecia areata study	Three male patients applied diclofenac 3% gel to the scalp nightly for management of actinic keratosis, significant hair regrowth was noted at the 4 and 6 month follow up appointments. ⁸⁵ Another study of diclofenac 1% gel applied twice daily for 2 months found significant hair regrowth. ⁸⁶

Active Ingredient Summary Table

Alopecia

Diphencyclopropenone	Acts as a contact allergen. The mechanism has not been fully elucidated, but it is hypothesized that the inflammatory response that is causing the hair loss is redirected	Alopecia areata ³¹ , Tested in men and women	Generally, an initial treatment of 2% is applied followed by a much lower concentration (perhaps 0.001%) after 2 weeks and gradually increased (on a weekly basis)	Response rate (considered to be 75% or greater terminal hair regrowth) in one study was 77% cumulatively and 17.4% for those suffering from alopecia totalis/universalis ^{31,35}
Dutasteride	Only known medication which blocks both type I and II 5-alpha reductase, more potent inhibition than finasteride, which shares a similar mechanism of action, resulting in inhibition of conversion of testosterone to DHT resulting in decreased DHT in serum and scalp ⁵¹	Androgenetic alopecia, studied in men ⁵¹ and women ⁵³	Orally 2.5mg in men ⁵² and 0.15mg orally in women ⁵³ Topical dutasteride studied at 0.01 to 0.05% found best results with 0.05% -> 1mL applied once daily ⁸⁷	One randomized double-blind controlled study compared topical dutasteride at 0.01%, 0.02%, and 0.05% to placebo or finasteride 1mg orally daily over a 24 week period. Patients in the topical treatment groups applied 1mL of solution daily via dropper bottle. The patients in the dutasteride 0.05% group demonstrated the most significant improvements in total area hair count and width over the 24 week period. ⁸⁷
EGCG (Green Tea Extract)	EGCG acts as an antioxidant and is thought to perhaps have some inhibitory effect on 5-alpha reductase therefore preventing formation of DHT. It may also stimulate growth of human dermal papilla cells via upregulation of phosphorylated Erk and Akt	Androgenetic alopecia ⁴¹ and possibly general hair loss as well	10% solution	An Ex vivo study found 10% EGCG solution to result in significant follicle elongation ⁴¹
Estradiol	A possible mechanism is estrogen induced increase in glycoprotein sex hormone-binding globulin leading to decreased free testosterone. ¹⁹	Androgenetic alopecia. Studied in women	0.025% topical lotion	One 6-month long study evaluating estradiol 0.025% topical lotion in patients with androgenetic alopecia found a decrease in hair loss, however, regrowth of new hairs was not demonstrated ¹⁹

Active Ingredient Summary Table

Alopecia

Finasteride	Inhibition of type II 5-alpha reductase inhibiting conversion of testosterone to DHT resulting in decreased DHT in serum and scalp. ^{8,9}	Androgenetic alopecia. Studied in men and women	0.005% solution to 1% gel (wide variability)	Finasteride 0.005% has been tested in men and women and statistically significant benefit was observed. ⁷ 1% finasteride gel formulation vs finasteride oral tablets in men and found efficacy with the topical gel. ⁸ 0.25% finasteride in combination with 3% minoxidil vs 3% minoxidil alone the combination therapy with significantly superior to minoxidil alone. ^{9,10}
Fluocinolone Acetonide	Immune suppression, as an autoimmune disorder, alopecia areata can be treated by immunosuppressant drugs	Alopecia areata ⁴⁷	0.2% Fluocinolone acetonide cream twice daily ⁴⁷	Fluocinolone ac 0.2% cream twice daily (under occlusion at night) found regrowth of hair in 54% of treatment group compared with 0% of vehicle group ⁴⁷
Flutamide	Proposed mechanism of action is inhibition of alpha reductase ⁶⁰	Androgenetic alopecia	2% gel	One randomized, double-blinded study evaluated flutamide 2% with minoxidil 5% vs minoxidil alone and found combination treatment significantly more effective. ⁷⁷
GHK-Cu (Copper Peptide or glycyl-L-histidyl-L-lysine copper complex)	GHK-Cu may promote fibroblast proliferation resulting in collagen synthesis which may in turn promote increased scalp health and blood flow to hair follicles. GHK-Cu also suppresses TGF-beta1 leading to hair shaft thickening and elongation ^{69,70}	Androgenetic alopecia	Data is mainly in vitro, some compounders use 0.05-0.5%	Human use studies not yet available.
Ketoconazole	Unclear mechanism of action, possibly due to anti-inflammatory effects ¹⁸	Androgenetic alopecia. Studied in men	2% lotion or shampoo	Some limited studies in humans of ketoconazole 2% lotion or shampoo have shown benefit for some patients, and other studies in mice have noted hair regrowth as well, though the improvement was not as significant as

Active Ingredient Summary Table

Alopecia

				minoxidil compared to the placebo group. ^{13,14,15,16}
Latanoprost	Prostaglandin mediated anagen induction. Latanoprost and bimatoprost are prostaglandin analogues ²⁰	Androgenetic alopecia. Studied in men	0.1% solution	Increased hair density observed with latanoprost 0.1% solution at 24 weeks as compared to placebo
Levocetirizine	Proposed mechanism of action consistent with cetirizine, reduction of prostaglandin D2, a mediator of inflammation. Levocetirizine is the R enantiomer of racemic cetirizine. ⁷³⁻⁷⁵	Androgenetic alopecia	Not currently studied, but given its increased potency compared to cetirizine 0.5% could be considered.	No human studies currently, theoretical benefit based off of studies with racemic form (cetirizine).
Melatonin	Though the mechanism of action isn't totally clear, melatonin appears to induce anagen phase. ²¹ Some have postulated this is due to its antioxidant properties and anti-apoptotic effects ²²	Androgenetic alopecia and general (non-cicatricial) hair loss. Benefits for both men and women	1ml of 0.1%	Melatonin 0.1% solution was applied to the scalps of these women resulting in increased hair growth as compared to the placebo group. ^{21,22}
Metformin	Thought to improve fibrosis through mediation of adenosine monophosphate-activated protein kinase (AMPK). ⁷⁹ AMPK activation is thought to be the mechanism behind improving insulin sensitivity as well. ⁸⁰	Central centrifugal cicatricial alopecia	10% cream applied once daily	One case report of two patients with central centrifugal cicatricial alopecia refractory to treatments such as steroids, minoxidil, and ketoconazole found success after 4 months of treatment with metformin 10% cream. ⁷⁹ Another case involved topical metformin 10% in combination with minoxidil 5% lotion, significant hair regrowth was noted after 8 months. ⁸⁰
Minoxidil	Topical vasodilator that prolongs anagen phase and increases the size of smaller hair follicles. Proposed mechanism involves	Androgenetic alopecia and general (non-cicatricial) hair loss. Benefits for both men and women	2-5% topical solution	Topical minoxidil has been well studied in both men and women at both 2 and 5%. Studies have demonstrated the superior efficacy of 5% minoxidil over

Active Ingredient Summary Table

Alopecia

	modulation of prostaglandin levels.			2% minoxidil twice daily with one study reporting 45% more hair growth in the 5% minoxidil group. ^{4,6}
Progesterone	Progesterone can inhibit conversion of testosterone to DHT. ⁸¹	Androgenetic Alopecia. Studied in female patients	Progesterone 2% 2mL applied once daily	One small study of female patients compared progesterone 2% (2mL applied daily) to minoxidil 2% and found that while benefit was greater in the minoxidil group, significant hair regrowth was noted in the progesterone group as well. ⁸¹
Rosemary Oil	May increase hair count via enhancement of microcapillary perfusion. ⁶⁵ Some data suggests anti-inflammatory and even some anti-antrogenic effects as well ⁶⁶	Androgenetic alopecia in both males and females	Concentration to use is not well established, some studies have looked at formulas with up to 10% rosemary oil ⁶⁷ another study looked at 1% rosemary oil, 1mL applied twice daily. ⁶⁸	One study of rosemary oil vs minoxidil 2% noted increases in hair count at the 6-month time point with no significant differences between groups. ⁶⁵
Sirolimus	Proposed mechanism of action is induction of anagen phase. ^{71,72}	Androgenetic alopecia	Up to 0.25%	Data is mainly in mice or vitro currently, but thus far has shown increased hair growth rate and hair follicle density with use of topical sirolimus. Studied concentrations have been quite low, on the mcg level, anecdotally, concentrations currently being used for human use are higher up to 0.25%. ^{71,72}
Spironolactone	Competitive inhibition of androgen receptors, systemically inhibits ovarian androgen production. ²⁴	Androgenetic alopecia. Studied in women	1% topical solution and oral use	One study of 60 female patients found a spironolactone 1% topical to be effective at promoting hair growth, however, the study has not been repeated and benefit has not been studied in men. ^{17,18}
Squaric Acid Dibutylester	Acts as a contact allergen. The mechanism has not been fully elucidated, but it is hypothesized that the inflammatory response	Alopecia areata ²⁷ Studied in men and women as well as children ²⁹	Generally, an initial treatment of 2% is applied followed by a much lower concentration (perhaps 0.001%) after 1-2	A prospective, double-sides patient-controlled trial found that sensitization with 2% SADBE followed by weekly application resulted in “excellent

Active Ingredient Summary Table

Alopecia

	that is causing the hair loss is redirected		weeks and gradually increased (on a weekly basis) until the pt has a reaction usually resulting in 0.01-1% final concentration for therapy ^{29,30}	response” in 60% of those treated on the treated sites. ²⁸ Another comprehensive review determined that 44.05% of patients using this therapy experienced at least 50% of terminal hair regrowth. ²⁹ Fun fact: A retrospective study found that topical irritants in combination with oral fexofenadine resulted in statistically significant greater hair regrowth ³⁷
Tacrolimus	Tacrolimus is a calcineurin inhibitor that suppresses the immune system	Alopecia areata and frontal fibrosing alopecia in male and female patients	Tacrolimus 0.1% applied twice daily	One study of tacrolimus 0.1% ointment applied twice daily for 24 weeks did not find benefit with this treatment, they noted it may be due in part to the ointment formulation. ⁸³ Another study that looked at tacrolimus 0.1% solution applied twice daily for one month, then once daily for one month, then every other day for four months found benefit for frontal fibrosing alopecia. ⁸⁴
Tea Tree Oil	Thought to treat alopecia via a combination of effects including anti-inflammatory antimicrobial,, and potentially impacting follicle sensitivity to androgens. ⁶⁶	Androgenetic alopecia. Applications in both male and female patients	5% tea tree oil applied 1mL twice daily	One study of combination minoxidil 5%, diclofenac 0.5%, tea tree oil 5%, 1mL applied twice daily for 32 weeks found greater improvement in hair count than the minoxidil alone group. ⁶⁶
Tofacitinib (Xeljanz)	Attenuation of inflammatory cascade via JAK inhibition may play a role ³⁹	Alopecia areata. Studied in both men and women	Has been used orally for alopecia areata, or topically at 1 to 2% solution for eyelashes ³⁹ or 2% ointment to the scalp (authors theorized oint may be bad vehicle choice) ⁴⁰	Case study of patient with alopecia areata of the eyelashes found that after 7mo of treatment with tofacitinib 2% solution eyelashes regrew completely. ³⁹ Another small study of 10 patients found improvement in 3 with the application of 2% ointment ⁴⁰

Active Ingredient Summary Table

Alopecia

Tretinoin	Known to increase percutaneous absorption of minoxidil therefore could assist in getting minoxidil to site of action ¹² Additionally, may have own benefit by causing contact dermatitis ³¹	Androgenetic alopecia, studied in men (though mechanism could also apply to women). Also alopecia areata, studied in men and women	Tretinoin 0.01% topical solution in combo with minoxidil ¹² or up to 0.05% as a solo agent ³¹	One study of once daily tretinoin 0.01% with minoxidil 5% vs twice daily minoxidil 5% found that once daily combination therapy was as effective as twice daily minoxidil treatment. ¹² In one study 0.05% tretinoin resulted in response from 55% of patients ^{31,36}
Valproic Acid	Inhibits glycogen synthase kinase 3-beta and activates other pathways (Wnt/beta-catenin), that are associated with hair growth cycle and the induction of anagen (growth) phase ⁴⁵	Studied in men with androgenetic alopecia, though could conceivably apply to other populations ⁴⁵	Sodium valproate 8.3% topical spray ⁴⁵	Study of 8.3% sodium valproate vs placebo spray for 24 weeks found mean increase in total hair count in VPA group as compared to placebo. No significant adverse events reported ⁴⁵

References:

- Rhodes T, Girman C, Savin R. Prevalence of male pattern hair loss in 18-49 year old men. *Dermatol Surg.* 1998; 24(12):1330-2.
- Levy L, Emer J. Female pattern alopecia: current perspectives. *Int J Womens Health.* 2013; 5: 541-556.
- Gordon K, Totsi A. Alopecia: evaluation and treatment. *Clin Cosmet Investig Dermatol.* 2011; 4: 101-106.
- Olsen E, Dunlap F, Funicella T. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. *J Am Acad Dermatol.* 2002; 47(3):377-85.
- Qi J, Garza L. An overview of alopecias. *Cold Spring Harb Perspect Med.* 2014; 4(3):a013615. 10.1101/cshperspect.a013615.
- Hoedemaker C, van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. *Australas J Dermatol.* 2007; 48(1):43-45.
- Mazzarella F, Loconsole F, Cammisa A, Mastrodonardo M, Vena GA. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. *J Dermatol Treat.* 1997; 8: 189-92.
- Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenic alopecia. *Indian J Dermatol Venereol Leprol.* 2009; 1(75): 47-51.
- Suchonwanit P, Srisuwanwattana P, Chalermroji N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs 3% minoxidil solution in the treatment of male androgenetic alopecia. *J Eur Acad Dermatol Venereol.* 2018;32(12):2257-2263. Doi: 10.1111/jdv.15171.
- Won Lee S, Juhasz M, Mobasher P, Ekelem C, Mesinkovska N. A systemic review of topical finasteride in the treatment of androgenetic alopecia in men and women. *Journal of Drugs in Dermatology.* 2018; 4(17): 457-463.
- Narasimhalu C. A cross-sectional randomized comparative study of topical minoxidil solution with and without finasteride in male pattern androgenetic alopecia in South Indian patients. *International Journal of Research in Dermatology.* 2018; 4(1):46-49.
- Shin H, Won C, Lee S, Kwon O, Kim K, Eun H. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss. *American Journal of Clinical Dermatology.* 2007; 8(5): 285-290.
- Inui S, Itami S. Reversal of androgenic alopecia by topical ketoconazole: relevance of anti-androgenic activity. *Journal of Dermatological Science.* 2007; 45(1): 66-68.

14. Pierard-Franchimont C, De Doncker P, Cauwenbergh G, Pierard G. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. *Dermatology*. 1999; 196(4):474-7.
15. Jian J, Tsuboi R, Kojima Y, Ogawa H. Topical application of ketoconazole stimulates hair growth in C3H/HeN Mice. *The Journal of Dermatology*. 2005; 32(4):243-7.
16. Aldhalimi M, Hadi N, Ghafil F. Promotive effect of topical ketoconazole, minoxidil, and minoxidil with tretinoin on hair growth in male mice. *ISRN Pharmacology*. Vol 2014, Article ID 575423, 5 pages, 2014. <https://doi.org/10.1155/2014/575423>.
17. Dill-Muller D, Zaun H. Topical treatment of androgenetic alopecia with spironolactone. *J Eur Acad Dermatol Venereol*. 1997 Sep;9(Suppl 1):31.
18. Shamsaldeen O, Mubki T, Shapiro J. Topical Agents for Hair Growth Promotion: What is Out There. *Skin Therapy Letter*. 2013; 18(4): <https://www.skintherapyletter.com/alopecia/growth-promotion/>
19. Orfanos CE, Vogels L. [Local therapy of androgenetic alopecia with 17-alphaestradiol. A controlled, randomized, double-blind study (author's transl)]. *Dermatologica*. 1980; 161(2):124-32
20. Blume-Peytavi U, Lonnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. *J Am Acad Dermatol*. 2012; 66(5): 794-800.
21. Fischer T, Burmeister, Schmidt, Elsner. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. *British Journal of Dermatology* 2004; 150: 341-345
22. Fischer T, Trueb R, Hanggi G, Innocenti M, Elsner P. Topical melatonin for treatment of androgenetic alopecia. *Int J Trichology*. 2012; 4(4):236-245
23. Dhurat P, Chitallia J, May T et al. An open-label randomized multicenter study assessing the noninferiority of a caffeine-based topical liquid 0.2% versus minoxidil 5% solution in male androgenetic alopecia. *Skin Pharmacol Physiol*. 2018; 30(6): 298-305
24. Q Dinh, R Sinclair. Female pattern hair loss: current treatment concepts. *Clin Interv Aging*. 2007; 2(2):189-199
25. Lenane P, Macarthur C, Parkin P. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children. *JAMA Dermatol*. 2014; 150(1):47-50. Doi:10.1001/jamadermatol.2013.5764
26. Tosti A, Piraccini B, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. *J Am Acad Dermatol*. 2003; 49(1):96-98
27. Micali G, Cicero R, Nasca M, Sapuppo A. Treatment of alopecia areata with squaric acid dibutylester. *Int J Dermatol*. 1996; 35(1):52-6
28. Chua S, Goh C, Ang C. Topical squaric acid dibutylester therapy for alopecia areata: a double-sides patient-controlled study. *Ann Acad Med Singapore*. 1996; 25(6):842-7
29. Zerbinati N, Esposito C, D'Este E, Calligaro A, Valsecchi R. Topical immunotherapy of alopecia areata: a large retrospective study. *Dermatol Ther (Heidelb)*. 2018; 8(1): 101-110
30. Tiwary A, Mishra D, Chaudhary S. Comparative study of efficacy and safety of topical squaric acid dibutylester and diphenylcyclopropenone for the treatment of alopecia areata. *North American Journal of Medical Sciences*. 2016; 6(8): 237-242
31. Alsantali A. Alopecia areata: a new treatment plan. *Clin Cosmet Investig Dermatol*. 2011; 4:107-115
32. Mancuso G, Balducci A, Casadio C, et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. *Int J Dermatol*. 2003;42(7):572-575
33. Fiedler-Weiss V, Buys C. Evaluation of anthralin in the treatment of alopecia areata. *Arch Dermatol*. 1987; 123(11):1491-3
34. Fiedler V, Wendrow A, Szpunar G, Metzler C, DeVillez R. Treatment-resistant alopecia areata. Response to combination therapy within minoxidil plus anthralin. *Arch Dermatol*. 1990; 126(6):756-9
35. Wiseman M, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. *Arch Dermatol*. 2001; 137(8):1063-8
36. Das S, Ghorami RC, Chatterjee T, Banerjee G. Comparative assessment of topical steroids, topical tretinoin (0.05%) and dithranol paste in alopecia areata. *Indian J Dermatol*. 2010; 55(2):148-9
37. Inui S, Nakajima T, Toda N, Itami S. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: retrospective analysis of 121 cases. *J Dermatol*. 2009; 36(6):323-7
38. Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. *J Am Acad Dermatol*. 2009; 61(4): 592.e1-9
39. Craiglow B. Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes. *JAAD Case Rep*. 2018; 4(10):988-989
40. Liu L, Craiglow B, King B. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. *J Am Acad Dermatol*. 2018; *Research Letters*:403-404
41. Kwon O, Han J, Yoo H et al. Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). *Phytomedicine*. 2007; 14: 551-555

Active Ingredient Summary Table

Alopecia

42. Trueb R. Serum biotin levels in women complaining of hair loss. *Int J Trichology*. 2016; 8(2): 73-77.
43. Hosking A, Juhasz M, Atanaskova M. Complementary and alternative treatments for alopecia: a comprehensive review. *Skin Appendage Disord* 2019; 5: 72-89
44. Patel D, Swink S, Castela-Soccio L. A review of the use of biotin for hair loss. *Skin Appendage Disord*. 2017; 3(3): 166-169.
45. Jo SJ, Shin H, Park YW et al. Topical valproic acid increase the hair count in male patients with androgenetic alopecia: a randomized, comparative, clinical feasibility study using phototrichogram analysis. *J Dermatol*. 2014; 41(4): 285-91.
46. Rossi A, Campo D, Fortuna MC. A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. *J Dermatolog Treat*. 2018; 29(2): 149-151.
47. Harries M, Sun J, Paus R, King L. Management of alopecia areata. *BMJ*. 2010; 341: c3671.
48. Arican O, Sasmaz S. Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. *Am J Clin Dermatol*. 2005; 6 (6): 403-6.
49. Pazoki-Toroudi H: The efficacy and safety of minoxidil 5% combination with azelaic acid 1/5% and caffeine 1% solution on male pattern hair loss (abstract). *J Invest Dermatol* 2013; 133:S84.
50. Gupta A. Azelaic acid: an update. *JAAD*. 2005; 52(3):P14.
51. Rafi A, Katz R. Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. *International Scholarly Research Notices*. 2011. <https://doi.org/10.5402/2011/241953>.
52. Olsen E, Hordinsky M, Whiting D et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. *J Am Acad Dermatol*. 2006; 55(6): 1014-23.
53. Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonchot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. *Indian J Dermatol Venereol Leprol*. 2014;80(6):521–525. doi:10.4103/0378-6323.144162
54. Thanomkitii K, Pruksaeakanan C, Subhookul C et al. Efficacy and safety of topical 5% azelaic acid solution versus 2% minoxidil solution in the treatment of female pattern hair loss. *Siriraj Medical Journal*. 2023; 75(12): 887-893.
55. Marotta J, Patel G, Carbalho M, Blakeney S. Clinical efficacy of a topical compounded formulation in male androgenetic alopecia: minoxidil 10%, finasteride 0.1%, biotin 0.2%, and caffeine citrate 0.05% hydroalcoholic solution. *Int Journ Pharm Comp*. 2020; 24(1): 69-76.
56. Yelich A, Jenkins H, Holt S, Miller R. Biotin for Hair Loss: Teasing Out the Evidence. *J Clin Aesthet Dermatol*. 2024;17(8):56-61.
57. Volker J, Koch N, Vecker M, Klenk A. Caffeine and its pharmacological benefits in the management of androgenetic alopecia: A review. 2020; 33(3): 153-169.
58. Mostafa D, Samadi A, Niknam et al. Efficacy of cetirizine 1% versus minoxidil 5% topical solution in the treatment of male alopecia: a randomized, single-blind controlled study. *J Pharm Pharm Sci*. 2021; 191-199.
59. Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. *Drugs*. 2023;83(8):701-715. doi:10.1007/s40265-023-01880-x
60. Koralewicz M, Szatkowska O. Topical solutions for androgenetic alopecia: evaluating efficacy and safety. *Forum Dermatologicum*. 2024; 10(3): 71-78.
61. Study Details | Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia. | [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 2025
62. Zaher H, Gawdat HI, Hegazy RA, Hassan M. Bimatoprost versus mometasone furoate in the treatment of scalp alopecia areata: A Pilot Study. *Dermatology*. 2015;230:308–13.
63. Tabri, Farida & Anwar, Anis & Adriani, Anni & Aryaningrum, Dwi. (2018). The Effectiveness of 0.03% Bimatoprost Solution Vs Minoxidil 5% in Androgenic Alopecia. *Indian Journal of Public Health Research & Development*. 9. 1444. 10.5958/0976-5506.2018.02056.9.
64. Rafati M, Mahmoudian R, Golpour M, Kazeminejad A, Saeedi M, Nakoukar Z. The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial. *Dermatologic Therapy*. 2022. <https://doi.org/10.1111/dth.15450>.
65. Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. *Skinmed*. 2015;13(1):15-21.
66. Bin Rubaian NF, Alzamami HFA, Amir BA. An Overview of Commonly Used Natural Alternatives for the Treatment of Androgenetic Alopecia, with Special Emphasis on Rosemary Oil. *Clin Cosmet Investig Dermatol*. 2024;17:2495-2503. Published 2024 Nov 5. doi:10.2147/CCID.S470989
67. Uronnachi E, Atuegwu C, Umeyor C et al. Formulation and evaluation of hair growth enhancing effects of oleogels made from rosemary and cedar wood oils. *Scientific African*. 2022; 16: e01223.
68. Tisserand, Hana. Rosemary essential oil is a promising alternative for hair growth promotion. <https://tisserandinstitute.org/learn-more/rosemary-essential-oil-hair-growth-promotion/> Accessed 2/12/2025.

69. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. *Int J Mol Sci.* 2018;19(7):1987. Published 2018 Jul 7. doi:10.3390/ijms19071987
70. Sadgrove NJ, Simmonds MSJ. Topical and nutricosmetic products for healthy hair and dermal antiaging using "dual-acting" (2 for 1) plant-based peptides, hormones, and cannabinoids. *FASEB Bioadv.* 2021;3(8):601-610. Published 2021 Jun 6. doi:10.1096/fba.2021-00022
71. Suzuki T, Chéret J, Scala FD, et al. mTORC1 activity negatively regulates human hair follicle growth and pigmentation. *EMBO Rep.* 2023;24(7):e56574. doi:10.15252/embr.202256574
72. Lin Y, Shao R, Xiao T, Sun S. Promotion of Hair Regrowth by Transdermal Dissolvable Microneedles Loaded with Rapamycin and Epigallocatechin Gallate Nanoparticles. *Pharmaceutics.* 2022;14(7):1404. Published 2022 Jul 4. doi:10.3390/pharmaceutics14071404
73. Walsh GM. The anti-inflammatory effects of levocetirizine--are they clinically relevant or just an interesting additional effect?. *Allergy Asthma Clin Immunol.* 2009;5(1):14. Published 2009 Dec 17. doi:10.1186/1710-1492-5-14
74. Wen S, Wei J, Bao J, et al. Effect of levocetirizine hydrochloride on the growth of human dermal papilla cells: a preliminary study. *Ann Palliat Med.* 2020;9(2):308-317. doi:10.21037/apm.2020.01.15
75. Albash R, El-Dahmy R, Hamed M et al. Repurposing levocetirizine hydrochloride loaded into cationic ceramide/phospholipid composite (CCPCs) for management of alopecia: central composite design optimization, in- silico and in-vivo studies. *Drug Delivery.* 2022; 1: <https://doi.org/10.1080/10717544.2022.2108939>
76. Sharma A, Gornen A, Shurat R et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. *Dermatologic Therapy.* 2019. <https://doi.org/10.1111/dth.12915>
77. Faghihi G, Iraj F, Siadat AH, Saber M, Jelvan M, Hoseyni MS. Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia. *J Cosmet Dermatol.* 2022;21(10):4447-4453. doi:10.1111/jocd.14788
78. Anjum M, Zulfiqar S, Chaudhary A et al. Stimulation of hair regrowth in an animal model of androgenetic alopecia using 2-deoxy-D-ribose. *Front. Pharmacol.* 2024. <https://doi.org/10.3389/fphar.2024.1370833>
79. Araoye E, Thomas J, Aguh C. Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. *JAAD Case Reports.* 2020; 6(2): 106-108.
80. Afshar K, Abidfard S, Nikbakht M et al. A systematic review on clinical evidence for topical metformin: old medication with new application. *Health Science Reports.* 2024; 7(12): <https://doi.org/10.1002/hsr2.70281>
81. Babaii N, Khodaiani E, Herizchi H. Comparison of effects of 2% topical minoxidil solution with 2% topical progesterone in the treatment of female pattern androgenetic alopecia. 2006; 28(2):19-22.
82. Unal M. Use of adapalene in alopecia areata: Efficacy and safety of mometasone furoate 0.1% cream versus combination of mometasone furoate 0.1% cream and adapalene 0.1% gel in alopecia areata. *Dermatol Ther.* 2018;31(1):10.1111/dth.12574. doi:10.1111/dth.12574
83. Price V, Willey A, Chen B. Topical tacrolimus in alopecia areata. *Journal of the American Academy of Dermatology.* 2005; 52(1): 138-139.
84. Scharf C, Licata G, Briatico G, Pellerone S, Argenziano G, Giorgio CM. Tacrolimus in Solution as an Option to Inflammatory Conditions of the Scalp. *Dermatol Pract Concept.* Published online April 1, 2023. doi:10.5826/dpc.1302a89
85. Collgros H, Joaquin SO, Iglesias-Sancho M. Topical diclofenac 3% gel for actinic keratosis may induce terminal hair in male androgenetic alopecia: A report of three cases. *Journal of Skin and Stem Cell.* 2015: DOI:10.17795/jssc33470
86. Sharquie K, Al-Nuaimy A, Kadhum W. Treatment of alopecia areata by topical diclofenac sodium gel in comparison to benzoyl peroxide gel. A novel single blind therapeutic clinical trial. *Saudi Med J.* 2006; 27(7): 1079-1081
87. Panuganti VK, Kumar Madala P, Ramalingayya Grandhi V, Varma Alluri C, Mohammad J, Rao Kssv S, Reddy Dundigalla M. A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia. *Cureus.* 2025 Aug 3;17(8):e89309. doi: 10.7759/cureus.89309. PMID: 40909044; PMCID: PMC12405733.